These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24323472)

  • 41. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
    Apgar JM; Wilkening RR; Parker DL; Meng D; Wildonger KJ; Sperbeck D; Greenlee ML; Balkovec JM; Flattery AM; Abruzzo GK; Galgoci AM; Giacobbe RA; Gill CJ; Hsu MJ; Liberator P; Misura AS; Motyl M; Nielsen Kahn J; Powles M; Racine F; Dragovic J; Fan W; Kirwan R; Lee S; Liu H; Mamai A; Nelson K; Peel M
    Bioorg Med Chem Lett; 2021 Jan; 32():127661. PubMed ID: 33160023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.
    Scorneaux B; Angulo D; Borroto-Esoda K; Ghannoum M; Peel M; Wring S
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rezafungin
    Helleberg M; Jørgensen KM; Hare RK; Datcu R; Chowdhary A; Arendrup MC
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
    Pfaller MA; Diekema DJ; Messer SA; Hollis RJ; Jones RN
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1068-71. PubMed ID: 12604543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The composition of the culture medium influences the β-1,3-glucan metabolism of Aspergillus fumigatus and the antifungal activity of inhibitors of β-1,3-glucan synthesis.
    Clavaud C; Beauvais A; Barbin L; Munier-Lehmann H; Latgé JP
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3428-31. PubMed ID: 22391552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.
    Beyda ND; Liao G; Endres BT; Lewis RE; Garey KW
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5405-12. PubMed ID: 26100700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
    Eschenauer GA; Nguyen MH; Shoham S; Vazquez JA; Morris AJ; Pasculle WA; Kubin CJ; Klinker KP; Carver PL; Hanson KE; Chen S; Lam SW; Potoski BA; Clarke LG; Shields RK; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(4):1897-906. PubMed ID: 24395235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
    Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
    Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
    Saribas Z; Yurdakul P; Cetin-Hazirolan G; Arikan-Akdagli S
    Mycoses; 2012 Mar; 55(2):156-60. PubMed ID: 21668525
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong
    Schell WA; Jones AM; Garvey EP; Hoekstra WJ; Schotzinger RJ; Alexander BD
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956419
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative Analysis of the Aspergillus fumigatus Cell Wall Modification and Ensuing Human Dendritic Cell Responses by β-(1,3)-Glucan Synthase Inhibitors-Caspofungin and Enfumafungin.
    Guilloux K; Hegde P; Wong SSW; Aimanianda V; Bayry J; Latgé JP
    Mycopathologia; 2024 Sep; 189(5):86. PubMed ID: 39302505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
    Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
    J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent.
    Staab JF; Kahn JN; Marr KA
    Antimicrob Agents Chemother; 2010 Dec; 54(12):4992-8. PubMed ID: 20855747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
    Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3528-35. PubMed ID: 23669387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare.
    Lockhart SR; Pham CD; Kuykendall RJ; Bolden CB; Cleveland AA
    Diagn Microbiol Infect Dis; 2016 Jan; 84(1):52-54. PubMed ID: 26429293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
    Desnos-Ollivier M; Bretagne S; Raoux D; Hoinard D; Dromer F; Dannaoui E;
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3092-8. PubMed ID: 18591282
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
    Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
    Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The mechanisms of resistance to echinocandin class of antifungal drugs].
    Niimi K; Niimi M
    Nihon Ishinkin Gakkai Zasshi; 2009; 50(2):57-66. PubMed ID: 19430179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.